All In Biotech

Drug Trial Radar · NCT05890001

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Apr 5, 2023

Primary completion

Oct 8, 2024

Study completion Oct 8, 2024

Sponsor

Lead sponsor
Braintree LaboratoriesIndustry
Sponsor type
Industry
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).

Conditions

  • Non-erosive Reflux Disease
  • Erosive Esophagitis

Interventions

  • BLI5100Drug

    Patients will take BLI5100 once daily, orally, for up to 29 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of treatment-emergent adverse eventsTime frame: 31 Weeks

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 24

    Huntsville, Alabama

  • Research Site 62

    Phoenix, Arizona

  • Research Site 27

    Tucson, Arizona

  • Research Site 87

    Little Rock, Arkansas

  • Research Site 117

    North Little Rock, Arkansas

  • Research Site 94

    Chula Vista, California

  • Research Site 10

    Huntington Park, California

  • Research Site 55

    La Mesa, California

  • Research Site 72

    Los Angeles, California

  • Research Site 54

    Los Angeles, California

  • Research Site 13

    Santa Ana, California

  • Research Site 41

    Santa Maria, California

  • Research Site 108

    Cooper City, Florida

  • Research Site 91

    Doral, Florida

  • Research Site 78

    Homestead, Florida

  • Research Site 23

    Maitland, Florida

  • Research Site 38

    Miami, Florida

  • Research Site 43

    Miami, Florida

  • Research Site 67

    Miami, Florida

  • Research Site 92

    Miami, Florida

  • Research Site 71

    Miami, Florida

  • Research Site 42

    Miami Lakes, Florida

  • Research Site 17

    New Port Richey, Florida

  • Research Site 90

    Ocoee, Florida

  • Research Site 05

    Palmetto Bay, Florida

  • Research Site 11

    Sunrise, Florida

  • Research Site 46

    Viera, Florida

  • Research Site 59

    Sandy Springs, Georgia

  • Research Site 01

    Gurnee, Illinois

  • Research Site 02

    Oak Lawn, Illinois

  • Research Site 45

    Houma, Louisiana

  • Research Site 12

    Marrero, Louisiana

  • Research Site 48

    Metairie, Louisiana

  • Research Site 34

    New Orleans, Louisiana

  • Research Site 111

    Chesterfield, Missouri

  • Research Site 06

    Las Vegas, Nevada

  • Research Site 64

    Reno, Nevada

  • Research Site 35

    Brooklyn, New York

  • Research Site 07

    Great Neck, New York

  • Research Site 28

    Hartsdale, New York

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.